Meeting
2022 ASCO Annual Meeting
Cost-effectiveness of targeted genomic risk provision to prevent skin cancer: Results of a randomized trial.
Authors
Chi Kin Law
NHMRC Clinical Trials Centre, University Of Sydney, Camperdown, NSW, Australia
Chi Kin Law , Amelia K Smit , Anne E. Cust , Lyndal Trevena , Pablo Fernandez Penas , Omgo E. Nieweg , Alexander M. Menzies , Sarah Wordsworth , Rachael L. Morton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Prevention
Clinical Trial Registration Number
ACTRN12617000691347
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10536)
DOI
10.1200/JCO.2022.40.16_suppl.10536
Abstract #
10536
Poster Bd #
412
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analyses of population-based multi-gene testing for the prevention of breast and ovarian cancer in the United States.
First Author: Fangjian Guo
Poster
2024 ASCO Breakthrough
Cost-effectiveness of liquid biopsy for molecular profiling of newly diagnosed advanced non-squamous NSCLC in an Asian population.
First Author: Aaron C. Tan
Poster
2024 ASCO Annual Meeting
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).
First Author: Syed Arsalan Ahmed Naqvi